| Identification | More | [Name]
(R)-(+)-N-Benzyl-1-phenylethylamine | [CAS]
38235-77-7 | [Synonyms]
R(+)-N-(1-PHENYLETHYL)BENZYLAMINE
(R)-(+)-N-BENZYL 1-METHYLBENZYLAMINE
(R)-N-BENZYL-1-PHENYLETHANAMINE
(R)-(+)-N-BENZYL-1-PHENYLETHYLAMINE
(R)-N-BENZYL-1-PHENYLETHYLAMINE
(R)-(+)-N-BENZYL-ALPHA-METHYLBENZYLAMINE
(R)(+)-N-BENZYL-ALPHA-PHENETHYLAMINE
R-(+)-N-BENZYL-A-METHYLBENZYLAMINE
R-(+)-N-benzyl-alpha-phenylethylamine
(R)-(+)-N-Benzyl-2-methylbenzylamine
(R)-(+)-N-BENZYL-ALPHA-METHYLBENZYLAMINE , 98% (97+% EE/HPLC)
R(+)-N-Benzyl-A-Phenylethylamine
(R)-(+)-N-Benzyl--methylbenzylamine
d-(+)-n-benzyl-à-methylbenzylamine
(R)-(+)-N-BENZYL-1-PHENYLETHYLAMINE: CHIPROS 99%, EE 96%
(R)-(+)-N-BENZYL-1-PHENYLETHYLAMINE, CHIPROS 99+%, EE 96+%
(R)-(+)-N-BENZYL-α-PHENYLETHYLAMINE
(R)-(+)-N-(1-Phenylethyl)benzylamine, (R)-(+)-N-Benzyl-1-phenylethylamine
(+)-N-Benzyl[(R)-α-methylbenzyl]amine
(R)-N-Benzyl-α-methylbenzenemethanamine | [EINECS(EC#)]
609-537-0 | [Molecular Formula]
C15H17N | [MDL Number]
MFCD00015010 | [Molecular Weight]
211.3 | [MOL File]
38235-77-7.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing .
S37/39:Wear suitable gloves and eye/face protection . | [RIDADR ]
2735 | [WGK Germany ]
3
| [HazardClass ]
8 | [PackingGroup ]
III | [HS Code ]
29214990 |
| Hazard Information | Back Directory | [Chemical Properties]
Colorless to light yellow liqui | [Uses]
(R)-(+)-N-Benzyl-α-methylbenzylamine may be used to prepare:
- tert-Butyl (3S)-3-{benzyl[(1R)-1-phenylethyl]amino}-3-(6-methoxypyridin-3-yl)propanoate, an intermediate for the synthesis of the Merck & Co. Inc., Kenilworth, NJ, U.S. αvβ3 integrin antagonist.
- A conformationally restricted piperidine-based analog of deoxynegamycin.
- 5- and 6-[2,3]-dihydrobenzofuran β-amino acids, which can act as aspartic acid mimetics.
|
|
|